Nasdaq

Greenwich LifeSciences Gets Fast Track Designation For GLSI-100

(RTTNews) - Greenwich LifeSciences, Inc. (GLSI) Wednesday said that it has received Fast Track Designation for GLSI-100 in the HLA-A*02 population of breast cancer patients. Key benefits of Fast Track ...
Nasdaq

Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation

STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, ...